摘要
目的探讨经皮选择性门静脉右支栓塞(PVE)在肝癌治疗中的应用价值。方法12例无手术切除指征的中晚期肝癌患者,在电视透视引导下经导管行经皮穿肝或穿脾行PVE。栓塞前、后用CT测量左侧肝叶的体积,并测量栓塞前后的门静脉压力、肝功能。结果12例患者均成功行经皮PVE,栓塞术后左肝叶代偿增生明显,其中3例PVE后顺利实行右肝切除术。PVE后未出现门静脉高压,肝功能损害轻,均未发现并发症。结论经皮选择性PVE能诱导非栓塞侧肝叶代偿性增生及栓塞侧肝叶萎缩,增加肿瘤手术切除机会,提高手术切除的安全性,对于无法手术切除的肝癌患者重新获得手术切除的机会,具有潜在的临床应用价值。
Objective To evaluate the clinical value of percutaneous transcatheter selective right portal vein embolization （PVE） in treatment of primary hepatocellular carcinoma. Methods Twelve patients with unresectable hepatocellular carcinoma were treated with right percutaneous transcatheter PVE under fluoroscopic guidance.Left hepatic lobe volume was measured by CT before and after PVE. Portal vein pressures and changes of liver function were also detected before and after the embolization. Results Right portal vein was embolized successfully in all 12 patients with compensatory hypertrophy of left hepatic lobe. Right hepatic lobe was successfully resected in 3 patients. There were no evidence of hepatic dysfunction and portal hypertension after PVE and also without complication. Conclusions Percutaneous transcathter portal vein branch embolization can induce atrophy of the embolized lobes with compensatory hypertrophy of the remnant liver, providing another operation chance for patients with unresectable hepatocellular carcinoma.
出处
《介入放射学杂志》
CSCD
2006年第11期664-666,共3页
Journal of Interventional Radiology
关键词
门静脉栓塞
介入治疗
肝癌
Portal vein embolization
Interventional therapy
Hepatocellular carcinoma
